PRODUCT INFORMATION

ABT-263-d_8

Item No. 34694

CAS Registry No.: 1217620-38-6
Formal Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl-d_8)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide
Synonym: Navitoclax-d_8
MF: $C_{47}H_{47}ClD_8F_3N_5O_6S_3$
FW: 982.7
Chemical Purity: ≥90% (ABT-263)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_8); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ABT-263-d_8 is intended for use as an internal standard for the quantification of ABT-263 (Item No. 11500) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

ABT-263-d_8 is supplied as a solid. A stock solution may be made by dissolving the ABT-263-d_8 in the solvent of choice, which should be purged with an inert gas. ABT-263-d_8 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of ABT-263-d_8 in these solvents is approximately 0.5, 25, and 30 mg/ml, respectively.

Description

ABT-263 is an inhibitor of the Bcl-2 family proteins Bcl-2, Bcl-xL, and Bcl-W (K_is = <1, <0.5, and <1 nM, respectively).[1] It is selective for Bcl-2, Bcl-xL, and Bcl-W over Mcl-1 and A1 (K_is = 550 and 354 nM, respectively). ABT-263 is cytotoxic in a panel of small cell lung cancer (SCLC), leukemia, and lymphoma cell lines with a mean EC_{50} value of 1 µM. It induces apoptosis in influenza A-infected retinal pigment epithelial cells (EC_{50} = 0.08 µM).[2] ABT-263 (100 mg/kg) induces tumor regression in NCI H146 SCLC and RS4;11 acute lymphocytic leukemia (ALL) mouse xenograft models.[1,3]

References

1. Tse, C., Shoemaker, A.R., Adickes, J., *et al.* ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* **68(9)**, 3421-3428 (2008).
2. Bulanova, D., Ianevski, A., Bugai, A., *et al.* Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins. *Viruses* **9(10)**, E271 (2017).
3. Shoemaker, A.R., Mitten, M.J., Adickes, S., *et al.* Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. *Clin. Cancer Res.* **14(11)**, 3268-3277 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM